Company research
Hemab Therapeutics Holdings, Inc.
CIK 2114044Updated Sep 29, 2026
SecurityCOAG · NASDAQ · equity
COAG price & chart
Loading TradingView…
NASDAQ:COAG on TradingView ↗About the company
We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches.
In the news
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering ↗
Recent filings
4 filing
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Offerings
Registration 333-294989
- Gross proceeds
- 301500000.0
- Net proceeds
- 280395000.0
- Deal price
- 18.0
- Shares
- 16750000
- Offering price
- $18.00
- Ticker
- COAG
Filing attachments
d180684dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d180684dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France New clinical data on HMB-002 demonstrated ≥ 2.4-fold increase in Von Willebrand Factor (VWF) and Factor VIII (FVIII), stronger than anticipated pr…
Read attachment ↗d102408dex991.htm · 8-K · 2026-05-21
EX-99.1 2 d102408dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Hemab Therapeutics Reports First Quarter 2026 Financial Results Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, MA, USA & COPENHAGEN, Denmark - May 21 2026 - Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatm…
Read attachment ↗d50309dex42.htm · S-1 · 2026-04-10
EX-4.2 5 d50309dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 WARRANTAFTALE WARRANT AGREEMENT Dato/Date: The English part of this document is an unofficial translation of the Danish text. In the event of disputes or misunderstandings arising from the translation, the Danish text shall prevail. WARRANTAFTALE WARRANT AGREEMENT INDGÅET MELLEM BETWEEN Hemab ApS Hemab ApS (CVR-nr. 40837590) (CBR-no. 40837590) (“Selskabet”) …
Read attachment ↗d50309dex43.htm · S-1 · 2026-04-10
EX-4.3 6 d50309dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 INVESTORS’ RIGHTS AGREEMENT This INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of March 30, 2026, by and among Hemab Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), the Investors (as defined below) and the Key Holders (as defined below). RECITALS WHEREAS, the Company, the Investors and the Key Holders are parties to that certain Share Contribution and Exchange Agreement of even date herewith by and among…
Read attachment ↗